Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in Australia
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
[68Ga]Ga-DPI-4452 · [177Lu]Lu-DPI-4452 — 10 sites
- TRIALPHASE2RECRUITING
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psilocybin therapy — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BNT329 · CA19-9-targeting monoclonal antibody — 16 sites
- TRIALPHASE1RECRUITING
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
MNPR-101-DFO*-89Zr · PET/CT Diagnostic Imaging — 1 site
- TRIALPHASE2RECRUITING
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AZD0901 · 5-Fluorouracil · Leucovorin — 52 sites
- TRIALPHASE3RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib · GnP · mGnP — 38 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab — 14 sites
- TRIALPHASE2RECRUITING
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Pembrolizumab · Olaparib — 17 sites
- TRIALPHASE1 / PHASE2RECRUITING
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
A novel hGIIA-Vimentin Inhibitor · Dose expansion — 3 sites
- TRIALPHASE1RECRUITING
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
MNPR-101-PCTA-177Lu — 1 site
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALPHASE1RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
LY4170156 · bevacizumab · carboplatin — 23 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
SBP-101 · Nab-paclitaxel · Gemcitabine — 93 sites
- TRIALPHASE1RECRUITING
A Study of MGC026 in Participants With Advanced Solid Tumors
MGC026 Dose Escalation · MGC026 Dose for Expansion — 12 sites
- TRIALPHASE2RECRUITING
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Pumitamig · Nab-paclitaxel · Gemcitabine — 24 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 220 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALPHASE1RECRUITING
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
KIVU-107 — 6 sites
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE2RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
BAY2927088 — 54 sites
- TRIALPHASE2RECRUITING
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
VS-7375 · cetuximab — 28 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Sacituzumab tirumotecan · Fluorouracil (5-FU) · Leucovorin (LV) or levoleucovorin — 55 sites
- TRIALPHASE2RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
HER3-DXd — 86 sites
- TRIALPHASE1NOT_YET_RECRUITING
Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC)
NRT6008 Injection · Systematic chemotherapy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Risvutatug Rezetecan · Drug 1 · Drug 2 — 85 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALPHASE3RECRUITING
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
daraxonrasib · gemcitabine · nab-paclitaxel — 25 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ifinatamab deruxtecan — 120 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.